Marta Martin-Gil - Publications

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Journal: JAMA oncology

Published: June 25, 2026

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Journal: Future oncology (London, England)

Published: April 07, 2026

Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 11, 2026

Early Supportive Versus Standard Care in Phase I Cancer Trials: A Randomized Controlled Trial.

Journal: Journal of pain and symptom management

Published: August 11, 2025

SEOM-GEICO clinical guidelines on endometrial cancer (2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 31, 2025

Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 30, 2025

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

Journal: Gynecologic oncology

Published: September 11, 2024

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Journal: BMC cancer

Published: July 29, 2024

SEOM-GEICO Clinical Guidelines on cervical cancer (2023).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 10, 2024

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Journal: Nature medicine

Published: April 24, 2024

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Journal: BMC cancer

Published: January 02, 2024

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 21, 2023